Monopar Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 71.91 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 482.67M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging ...